For research use only. Not for therapeutic Use.
BML-259 is a potent cyclin-dependent kinase 5 (Cdk5) inhibitor, with IC50s of 64 and 98 nM for Cdk5 and Cdk2, respectively[1].
BML-259 (10 μM) protects large population of cells against non-Aβ component of Alzheimer’s disease amyloid (NAC)-evoked cell death[2].
| Catalog Number | R036130 |
| CAS Number | 267654-00-2 |
| Synonyms | 2-phenyl-N-(5-propan-2-yl-1,3-thiazol-2-yl)acetamide |
| Molecular Formula | C14H16N2OS |
| Purity | ≥95% |
| InChI | InChI=1S/C14H16N2OS/c1-10(2)12-9-15-14(18-12)16-13(17)8-11-6-4-3-5-7-11/h3-7,9-10H,8H2,1-2H3,(H,15,16,17) |
| InChIKey | IGRZXNLKVUEFDM-UHFFFAOYSA-N |
| SMILES | CC(C)C1=CN=C(S1)NC(=O)CC2=CC=CC=C2 |
| Reference | [1]. Kaźmierczak A, et al. A novel mechanism of non-Aβ component of Alzheimer’s disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5). Neurochem Int. 2011;58(2):206-214. |
